Article ; Online: Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
Journal of the neurological sciences
2021 Volume 427, Page(s) 117501
Abstract: During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions ... treated with ocrelizumab are still lacking. Our findings suggest that a personalized treatment ... the therapeutic window for an effective response to SARS-CoV2 vaccine. ...
| Abstract | During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according to the national recommendations. Out of the 83 RRMS patients whose infusion was scheduled between March and December 2020, 56 patients experienced a delay in treatment based on MS severity and SARS-CoV2 infection risk profile. In most cases, the immunophenotype was performed monthly to guide re-infusions. Specifically, B CD19 + cells repopulation rate was monitored. Mean infusion delay was 103,1 [SD 40,6] days, and none of the patients presented relapses or active disease at MRI at the end of the observation period. Treatment naïve status and the interval between immunophenotyping and the last ocrelizumab infusion were predictors of earlier B CD19 + cells repopulation. Two patients contracted SARS-CoV2 with complete recovery. Definitive data about Sars-Cov2 vaccine efficacy in patients treated with ocrelizumab are still lacking. Our findings suggest that a personalized treatment with a delayed infusion schedule does not compromise ocrelizumab short-term efficacy and may help to lengthen the therapeutic window for an effective response to SARS-CoV2 vaccine. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Antibodies, Monoclonal, Humanized ; COVID-19 ; Humans ; Multiple Sclerosis ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/epidemiology ; Pandemics ; RNA, Viral ; SARS-CoV-2 | |||||
| Chemical Substances | Antibodies, Monoclonal, Humanized ; RNA, Viral ; ocrelizumab (A10SJL62JY) | |||||
| Language | English | |||||
| Publishing date | 2021-05-20 | |||||
| Publishing country | Netherlands | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 80160-4 | |||||
| ISSN | 1878-5883 ; 0022-510X ; 0374-8642 | |||||
| ISSN (online) | 1878-5883 | |||||
| ISSN | 0022-510X ; 0374-8642 | |||||
| DOI | 10.1016/j.jns.2021.117501 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 308: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.